-

Hims & Hers Now Offering a Dual-Action Topical Hair Loss Treatment for Men

Harnessing the Powers of Finasteride and Minoxidil In A Single Spray, The Convenient Prescription Treatment Can Help Regrow Hair and Prevent Future Hair Loss

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers, the multi-specialty telehealth platform that provides modern personalized health and wellness experiences to all consumers, is now offering men access to a convenient treatment for hair loss that combines two clinically-proven ingredients into a single spray. The Topical Finasteride & Minoxidil Spray is a pill-free prescription alternative to traditional oral finasteride treatment that provides effective support for male pattern hair loss. Featuring minoxidil 6% and finasteride 0.1%, the spray is available for appropriate customers with a prescription from a licensed medical professional through Hims & Hers platform, with consultations available at www.forhims.com.

The latest in a long list of high quality personalized wellness treatments available through the Hims & Hers telehealth platform, the combination of ingredients is specifically formulated to stop hair loss and regrow hair. Compared to oral finasteride that enters your bloodstream through taking pills, men can experience the benefits of finasteride treatment at lower concentrations to their bloodstream from the topical version through direct contact on their scalp. The dual-action spray works to block the production of the DHT hormones, which contribute to the damaging and closing of hair follicles. At the same time, the topical minoxidil helps to reactivate dormant hair follicles, increasing the length of the active growth phase and ultimately helping regrow hair.

“Hair loss will never be a one-size-fits-all experience, and neither should the way we treat it,” commented Hims & Hers Co-Founder and CEO Andrew Dudum. “We heard from our customers that they wanted more options to treat their hair loss—and in offering the two top-used ingredients that treat hair loss and growth in one really clean and simple-to-use form factor with the Topical Finasteride & Minoxidil Spray, men can experience the benefits of both these treatments in a convenient and efficient way.”

Finasteride treatments are commonly provided orally, but Hims & Hers customers have stated that they’d like to have an alternative to taking pills. In the same vein, the Hims & Hers team has heard from some customers that they’d like to have a drip-free, fine mist experience when applying a topical hair treatment – versus the dropper that some men find inconvenient for their hair type. To address these concerns, Hims & Hers is proud to now offer access to two clinically-proven ingredients in a less messy, convenient Topical Finasteride & Minoxidil Spray, a completely topical product that dries quickly with no drips or need for oral medication.

“With the addition of prescription Topical Finasteride & Minoxidil Spray, Hims is a leader in providing customizable offerings for hair loss in men,” said Hims & Hers’ Chief Medical Officer Dr. Patrick Carroll. “Hims’ suite of hair loss products can provide a high level of personalization for men who are seeking the optimal treatment for their own hair loss journey.”

The spray is available only with a prescription and requires a telehealth consultation with a medical professional through the Hims & Hers platform before beginning use.

For more details please visit www.forhims.com.

About Hims & Hers

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Contacts

Linda O'Connor
press@forhims.com

Hims & Hers

NYSEAM:HIMS

Release Summary
Hims & Hers has created an all-new treatment for hair loss that combines two of the most effective ingredients into a single spray.
Release Versions

Contacts

Linda O'Connor
press@forhims.com

More News From Hims & Hers

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care....

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa...
Back to Newsroom